NouvNeu001 is the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to receive this designation
Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach
Products manufactured at the new Vaughan facility will support research in areas including cancer, infectious disease, mental health, and environmental safety
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
Sun Pharma's Halol plant gets OAI classification from US FDA inspection
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
Vonvendi is the only recombinant Von Willebrand factor replacement therapy with approved indications in adults and children with VWD
The medicine was well tolerated, with no unexpected safety issue
Goyal reaffirmed the government’s commitment to facilitating market access, reducing trade barriers, and ensuring that Indian exporters remain globally competitive
Subscribe To Our Newsletter & Stay Updated